Receptor CXCR4 on cancer cells at the primary tumor site responds to CXCL12/Stromal-derived factor-1α, which is secreted into circulation by osteoblasts, inducing chemotaxis and further homing to and accumulation in the bone. Here, CXCL12 is linked to neoplasm.